ライフサイエンスコーパス: drop out

1 r VEGF, suggesting AT rarefaction (capillary drop out).

2 zed to stop IFN treatment and 25 to taper (1 drop-out).

3 tinctive skin lesions reflective of vascular drop out.

4 who experienced sedation were more likely to drop out.

5 ly missing, and collecting data on intent to drop out.

6 s showed dose-dependent FeSO(4)-induced cone drop out.

7 the use of motivational strategies to reduce drop-out.

8 es as homozygotes when one of the two copies drops out.

9 mine group and 58 (50%) in the placebo group dropped out.

10 Of the 33 patients enrolled, three dropped out.

11 tron group and 53 (16%) in the placebo group dropped out.

12 ted treatment for 26 weeks, and six patients dropped out.

13 One patient in the exercise group dropped out.

14 d immunodeficiency syndrome or died, and 173 dropped out.

15 Four patients dropped out 1 year after start of treatment.

16 s will be randomized (alpha 0.05, power 90%, drop-out 10%).

17 In total, 162 patients dropped out (20.7%), all from Group BDLT (P < 0.0001).

18 analysis that imputed data for patients who dropped out, 65.0% (95% CI, 51.6% to 76.9%) of the TwHF

19 patients were listed for LT (group LLT); 26 dropped-out (7.1%), 340 finally underwent PLT (group PLT

20 to hospital than were those assigned to IPS (drop-out 70 [45%] vs 20 [13%]; difference -32.1% [95% CI

21 % (24/240) did not remit, and 28.3% (68/240) dropped out; 70% (169/240) met response criteria.

22 One patient with Sezary syndrome dropped out after 1 week for personal reasons.

23 Six patients dropped out after 12 months of PFD.

24 ediately, 59% dropped out by week 12, and 7% dropped out after 12 weeks.

25 Thirty participants dropped out after assignment to 3 experimental groups; 9

26 g protocol, and an additional three patients dropped out after the imaging session at completion of 1

27 ernatively, censoring of follow-up data (ie, dropping out) after selective crossover.

28 ects included those participants who did not drop out and had evaluable outcome and cost data at 12 w

29 gical problems; for example, higher rates of drop out and of repeated participation.

30 PM treatment protected against capillary drop-out and limited laminin protein upregulation and EC

31 on to incorporating a probability of allelic drop-out and other critical parameters, Lab Retriever co

32 otal, 199 patients were enrolled, of whom 62 dropped out and 131 underwent transplantation at our ins

33 eria that were undetected at entry, 8 (7.5%) dropped out, and 7 (6.5%) were removed for clinical reas

34 Three patients dropped out, and final analyses were performed on 20 com

35 We demonstrate that Hb and drop-out are mainly a function of stochastic effect of p

36 For patients who drop out because of the side-effects of oral administrat

37 Two patients in the 20 mg/day group dropped out because of adverse effects, but the other do

38 Four DHEA and one placebo group patient dropped out because of adverse effects.

39 n dropped out because of pregnancy, 23 women dropped out because of other reasons, and 27 women compl

40 Seven women dropped out because of pregnancy, 23 women dropped out b

41 had congestive heart failure; three patients dropped out because of significant asymptomatic LVEF dec

42 Six patients died, and 2 patients dropped out because they were not willing to continue th

43 Seventy-one patients dropped out before liver transplantation (rate, 11.5% in

44 asons and 3 cases by inevitable reasons were dropped out before pollen.

45 before study termination (including one who dropped out before receiving study treatment), and 139 (

46 one group and three in the comparator group) dropped out before receiving their study drug.

47 nded at least one postbaseline visit but who dropped out before the 12-week visit).

48 Five patients dropped out before the 18-week followup visit.

49 se of study treatment; data for patients who dropped out before the end of the study were carried for

50 24 did not receive the programme, and three dropped out before the trial started.

51 ticipants across all psychosocial treatments dropped out before treatment completion compared to 44.6

52 Of these, 34% dropped out immediately, 59% dropped out by week 12, and 7% dropped out after 12 week

53 overall treatment failure rate (relapse and dropping out combined) was significantly lower for cogni

54 Arteries were also examined for signal drop-out (dephasing) on phase-contrast angiograms; depha

55 d for oGTTs at 15-month intervals until they dropped out, developed diabetes, or reached 12 years pos

56 the drop-out rate was 30%, but subjects who dropped out did not differ from those who completed the

57 Here we show that mutations in drop out (dop) disturb the segregation of membrane corti

58 No patients dropped out due to operation before an end-point was rea

59 he waiting list, 3 of 52 patients (5.8%) had dropped out due to tumor progression.

60 66 patients dropped out during phase one.

61 Three patients dropped out during the course of 8 years.

62 tient withdrew after randomisation and seven dropped out during the study.

63 f the constructs tested, the gene III and AP drop-out efficiency was between 90% and 100%.

64 ording to the predicted risk of dropout, and drop-out equivalent MELD (deMELD) points were calculated

65 r challenge is how to deal with the frequent drop-out events.

66 asons and 3 cases by inevitable reasons were dropped out for 2 years.

67 ipation after randomisation and two patients dropped out for administrative reasons.

68 ovides better tumor control and could reduce drop-out from transplant waitlists.

69 Seventy patients completed the trial (3 dropped out from the placebo group and 2 from the FMT gr

70 sed significantly and the number of patients dropping out from the waiting list because of advanced s

71 Of these, 34% dropped out immediately, 59% dropped out by week 12, and

72 The higher risk of drop out in patients outside Milan, and even within Mila

73 73 patients; P=0.092), likely owing to early drop out in the MTX group.

74 omized in each treatment arm, and 2 patients dropped out in both treatment arms.

75 per-protocol analysis, except for those who dropped out in the per-protocol analysis.

76 les are correctly called and allelic drop-in/drop-out is not observed.

77 A novel drop-out linker scheme was used to rapidly assess three-

78 Differential drop out may however cloud interpretation of data.

79 However, many people drop out of educational programs, such as community coll

80 arch on this population, including those who drop out of or never access health services, is needed t

81 es more likely than nondepressed patients to drop out of prolonged exposure therapy.

82 more likely to have mental health problems, drop out of school, and become pregnant.

83 vessel tortuosity at 2-month follow-up, with drop out of small abnormal vessels and straightening of

84 bunit of this enzyme cause photoreceptors to drop out of the eye disc epithelium and move toward and

85 l services were significantly more likely to drop out of the service and to be readmitted to hospital

86 s where some patients will be more likely to drop out of the waitlist than receive a transplant.

87 Subjects receiving DBT were less likely to drop out of treatment (hazard ratio, 3.2; P < .001) and

88 ma Prevention Study relates to the selective drop-out of treated and untreated patients with higher i

89 Fewer patients dropped out of combined treatment vs ADM treatment alone

90 sleepwalking, treated with benzodiazepines, dropped out of follow-up testing and reported persistenc

91 For individuals who had already dropped out of school at baseline, we detected no signif

92 Repeating a school year or having ever dropped out of school was not more common among children

93 Overall, 26% of enrolled patients dropped out of the acute phase treatment for nonmedical

94 e proportion of patients who responded to or dropped out of the allocated treatment.

95 he progeny of binucleate cells progressively dropped out of the cell cycle and expressed p53/p21, and

96 trial, 12 (9.9%) and 15 (12.6%) participants dropped out of the high-fiber and AHA diet groups, respe

97 t percent of the cohort experienced death or dropped out of the list due to medical condition deterio

98 The number of participants who dropped out of the studies because of adverse events was

99 195 of 508 of patients (38%) dropped out of the study (28% in strategy 4 vs. 40% to 4

100 82 patients dropped out of the study because of adverse events, with

101 Three subjects dropped out of the study because they were apprehensive

102 Thirty participants dropped out of the study prematurely, 22 in the nefazodo

103 ears, 36.2% of the original participants had dropped out of the study, and 30.9% had not yet reached

104 ntinued to have disease remission, and 22.1% dropped out of the study.

105 isease remission at the study end, and 16.8% dropped out of the study.

106 At day 10, three women had dropped out of the study.

107 nt groups; 23 of these patients subsequently dropped out of the study.

108 Subsequently, 5 patients dropped out of the study.

109 66 (21%) participants dropped out of the study.

110 Ten patients dropped out of the transfusion group, and two patients c

111 cations, tear film factors, and QST metrics) dropped out of these models.

112 Significantly more patients dropped out of treatment with imipramine than with fluox

113 Of the 127 participants randomized, 7 (5.5%) dropped out of treatment.

114 The impact on the proportion of children who dropped out of vaccination services after receiving 1 do

115 reduction in the proportion of children who dropped out of vaccination services.

116 association is driven by depressed persons' dropping out of religious activities is not clear.

117 ance use (>84%), depressive symptoms (>32%), dropping out of school (>57%), and residential instabili

118 n a broad spectrum of measures, ranging from dropping out of school to experiencing disability in one

119 child and midlife development (e.g., low IQ, dropping out of school, poor mental health, and being pa

120 held true despite more severely ill patients dropping out of the study in the usual-detection area.

121 ients either experiencing disease relapse or dropping out of the study.

122 y race between patients completing and those dropping out of the study.

123 mine patterns and predictors associated with dropping out of treatment.

124 Surprisingly, the DNA drops out of the binding cleft with a total loss of base

125 103 families dropped out or were lost to follow up.

126 No patients dropped out or were lost to follow-up in study 1; in stu

127 26 (0.3%) individuals dropped out or were lost to follow-up.

128 lacebo group and one in the pitrakinra group dropped out or were lost to follow-up.

129 setron; one patient in the ondansetron group dropped out owing to accidental injury.

130 balance (Hb) and the probability of allelic drop-out p(D).

131 the transfer process, we have constructed a "drop-out" phagemid vector that can be rapidly converted

132 The results are limited by an important drop out rate.

133 An 11.5% drop-out rate after 3.5 months of therapy indicates the

134 However, the trial was limited by a high drop-out rate and longer-term effects of the drug requir

135 The difference in the drop-out rate between groups was mainly due to a greater

136 The median DTP1-DTP3 drop-out rate was 14%, which equates to an additional 12

137 ng subjects with longitudinal follow-up, the drop-out rate was 30%, but subjects who dropped out did

138 Annualized cancer detection and drop-out rates were also approximated based on the obser

139 Drop-out rates were similar in the sertraline/placebo vs

140 performed a short hairpin RNA (shRNA)-based drop-out screen to identify novel genes and pathways tha

141 Yeast colonies of different size appear on 'drop-out' selection plates with small clones consistentl

142 se who do receive assistance, more than half drop out shortly thereafter.

143 st observation carried forward for those who dropped out, showed that subjects on the low-carbohydrat

144 nome-wide approach in which we carried out a drop-out shRNA screen using a whole genome library that

145 tend to have earlier sexual debut and school drop-out, so an association might be expected.

146 ication and talk therapy were less likely to drop out than those who received single-modality treatme

147 ubsequently, restriction digestion with AscI drops out the AP coding region and religation generates

148 restriction enzyme digestion with MfeI (to "drop-out" the gene III coding sequence), which generates

149 ied out in 50 Japanese adult MHD patients (1 dropped out); the primary outcome was the change in the

150 The main reason for participant drop out was migration out of the study area.

151 Twenty percent of subjects dropped out, with half (10% of the overall group) due to

152 patients were enrolled in the trial, and 22 dropped out within 4 months.